1. Eli Lilly to attend Bank of America Healthcare Conference on May 15, 2025. 2. CFO Lucas Montarce will discuss Lilly's opportunities in a fireside chat. 3. Conference may provide insights on Lilly's market strategies and innovations. 4. Lilly emphasizes advancements in diabetes, obesity, and cancer treatments. 5. Webcast available live and for replay on Lilly's investor website.
Participation in the conference can increase investor confidence and interest. Historical examples show stock price rises following important conferences or presentations.
The article discusses an upcoming event that could significantly influence perception and investment in LLY.
The conference is soon and likely to generate immediate interest. Previous conferences have resulted in quick spikes in trading volume and price.
INDIANAPOLIS, May 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 11:40 a.m., Eastern time.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website. A replay of the presentation will be available on this same website for approximately 90 days.
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to:
Ashley Hennessey; ashley.hennessey@lilly.com; 317-416-4363 (Media)
Michael Czapar; michael.czapar@lilly.com; 317-617-0983 (Investors)
SOURCE Eli Lilly and Company